The goal of this study is to test the impact of a virtual heart failure optimization program on uptake of guideline directed medical therapy, participation in cardiac rehabilitation \& impact on echocardiographic parameters.
This is a single center, prospective pre-post cohort study testing a virtual, multi-disciplinary heart failure optimization program for up-titration of guideline directed medical therapy. This nurse and kinesiologist-led program will start and up-titrate patients on GDMT and offer virtual cardiac rehabilitation over a 3-month period. The investigators hypothesize that this program could safely achieve higher rates of maximally tolerated ARNI, Beta-blocker, MRA and SGLT2i rates, as well as participation in cardiac rehabilitation among HFrEF patient participants. The investigators hypothesize that participation will lead to improved Left Ventricular Ejection Fraction on Echocardiogram.
Study Type
OBSERVATIONAL
Enrollment
400
Participants referred to the "Virtual Heart Failure Optimization Program" will be seen for initial consultation by a HF program nurse and cardiologist within 1 week. Patients will be offered the opportunity to participate in virtual cardiac rehabilitation. Following this, patients will be assessed virtually every two weeks by a HF program nurse for addition and up-titration of medical therapy. All medication changes will be performed algorithmically and reviewed with the overseeing cardiologist. Following all medication changes, appropriate monitoring will be performed algorithmically as well. All participants will be asked if they would like to participate in cardiac rehabilitation and an automatic referral will be sent by the overseeing cardiologist. Virtual cardiac rehabilitation will be conducted weekly with phone follow-up appointments with a program kinesiologist and virtual education programming.
Cambridge Cardiac Rehab
Cambridge, Ontario, Canada
RECRUITINGChange from baseline Doses of GDMT
Beta-blocker, ACE-inhibitor/Angiotensin receptor blocker/Valsartan-Sacubitril, Mineralocorticoid Receptor Antagonist, SGLT2 inhibitor
Time frame: After completion of program (3 months)
Change from baseline Left Ventricular Ejection Fraction
Measured in Transthoracic Echocardiogram
Time frame: After completion of program (3 months)
Change from baseline NYHA Classification
Stage of Heart Failure (I-IV, IV is worse)
Time frame: After completion of program (3 months)
Change from baseline Left Ventricular Mass Index
Measured by Transthoracic Echocardiogram
Time frame: After completion of program (3 months)
Change from baseline Left Ventricular End Diastolic Diameter
Measured by Transthoracic Echocardiogram
Time frame: After completion of program (3 months)
Change from baseline Left Ventricular End Systolic Diameter
Measured by Transthoracic Echocardiogram
Time frame: After completion of program (3 months)
Change from baseline Serum Potassium
Time frame: After completion of program (3 months)
Change from baseline eGFR
Time frame: After completion of program (3 months)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Change from baseline Systolic Blood Pressure
Time frame: After completion of program (3 months)
Change from baseline Diastolic Blood Pressure
Time frame: After completion of program (3 months)
Change from baseline Heart Rate
Time frame: After completion of program (3 months)
Change from baseline Body Mass Index
Time frame: After completion of program (3 months)